Αρχική World News Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients... World News Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among Patients with NSCLC and the Risk of Death From Any Cause Among Patients with Solid Tumours Από Ogkologos - 7 Μαΐου, 2025 795 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the analysis of TRACERx and MSK-IMPACT studies Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated... 13 Οκτωβρίου, 2022 FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer 23 Απριλίου, 2021 Immunotherapy’s Skin Side Effects: Are Microbes to Blame? 13 Ιουλίου, 2022 Mom’s Early-Stage Breast Cancer Discovered When She Undergoes Testing to Donate... 21 Αυγούστου, 2019 Φόρτωση περισσοτέρων HOT NEWS ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... New Blood Test Can Screen For Over 50 Cancers SBRT Emerging as an Important Treatment for Early-Stage Kidney Cancer FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy